Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France

NCT02785354 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02785354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02785354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
March 1, 2016
Completion date
April 5, 2016
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation